FrancophonIA/ELRC3.0 huggingface dataset:
English: In the Phase III newly diagnosed chronic phase CML study, the following grade 3 or 4 laboratory abnormalities were reported after a minimum of 12 months follow-up in patients taking SPRYCEL: neutropaenia (21%), thrombocytopaenia (19%), and anaemia (10%).
Danish: I fase III-studiet vedrørende nyligt diagnosticeret CML i kronisk fase er følgende grad 3 eller 4 afvigelser i laboratorieundersøgelser rapporteret efter mindst 12 måneders opfølgning hos patienter, der tog SPRYCEL: neutropeni (21%), trombocytopeni (19%) og anæmi (10%).
English: Uncommon anxiety, confusional state, affect lability, libido decreased Nervous system disorders
Danish: Ikke almindelig angst, konfusion, affektlabilitet, nedsat libido Nervesystemet
English: Therefore, in patients receiving dasatinib, coadministration of alternative medicinal products with less potential for CYP3A4 induction should be selected (see section 4.5).
Danish: Til patienter, der får dasatinib, bør der derfor vælges alternative midler, der har mindre potentiale for CYP3A4-induktion (se pkt.
English: Non-haematologic adverse reactions
Danish: Ikke-hæmatologiske bivirkninger
English: Further efficacy results are reported in Table 11.
Danish: Yderligere effektresultater fremgår af Tabel 11.
English: c Includes brain natriuretic peptide increased, ventricular dysfunction, left ventricular dysfunction, right ventricular dysfunction, cardiac failure, cardiac failure acute, cardiac failure chronic, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy, diastolic dysfunction, ejection fraction decreased and ventricular failure, left ventricular failure, right ventricular failure, and ventricular hypokinesia.
Danish: c Inkluderer forhøjet natriuretisk peptid i hjernen, ventrikel dysfunktion, venstre ventrikel dysfunktion, højre ventrikel dysfunktion, hjertesvigt, akut hjertesvigt, kronisk hjertesvigt, kongestiv hjertesvigt, kardiomyopati, kongestiv kardiomyopati, diastolisk dysfunktion, nedsat uddrivningsfraktion og ventrikelsvigt, venstre ventrikelsvigt, højre ventrikelsvigt og ventrikel-hypokinesi.
English: No additional patients were reported to have QTcF > 500 msec after a minimum of 60 months follow-up.
Danish: Efter mindst 60 måneders opfølgning blev der ikke rapporteret om yderligere patienter med QTcF > 500 msek.
English: Abdominal pain Diarrhoea
Danish: Opkastning Mavesmerter Diarré
English: The other ingredients are: sucrose, carmellose sodium, simethicone emulsion (consisting of simeticone, polyethylene glycol sorbitan tristearate, polyethoxylate stearate, glycerides, methylcellulose, xanthan gum, benzoic acid, sorbic acid, sulfuric acid), tartaric acid, trisodium citrate anhydrous, sodium benzoate (E211), silica hydrophobic colloidal, mixed berry flavour (containing: benzyl alcohol, sulphur dioxide) (see section 2 "What you need to know before you take SPRYCEL").
Danish: Øvrige indholdsstoffer: saccharose, carmellosenatrium, simeticonemulsion (bestående af simeticon, polyethylenglycolsorbitantristearat, polyethoxylatstearat, glycerider, methylcellulose, xanthangummi, benzoesyre, sorbinsyre, svovlsyre), vinsyre, vandfrit trinatriumcitrat, natriumbenzoat (E211), hydrofobisk silicakolloid, blandet bærsmag (indeholder: benzylalkohol, svovldioxid) (se afsnit 2 "Det skal du vide, før du begynder at tage SPRYCEL").
English: Of the 2,182 patients with resistance or intolerance to prior imatinib therapy who received dasatinib in clinical studies, 15 (1%) had QTc prolongation reported as an adverse reaction.
Danish: Blandt de 2.182 patienter med resistens eller intolerans over for tidligere behandling med imatinib, som fik dasatinib i kliniske studier, blev QTc-forlængelse indberettet som bivirkning hos 15 (1%) patienter.
English: Therefore, CYP3A4 substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) should be administered with caution in patients receiving dasatinib (see section 4.4).
Danish: CYP3A4-substrater, der vides at have et snævert terapeutisk indeks (fx astemizol, terfenadin, cisaprid, pimozid, quinidin, bepridil eller sekalealkaloider [ergotamin, dihydroergotamin]), skal derfor administreres med forsigtighed til patienter, der får dasatinib (se pkt.
English: 101 were randomised to dasatinib and 49 to imatinib (all imatinib-resistant).
Danish: Der foreligger resultater for 150 patienter: 101 var randomiseret til dasatinib og 49 til imatinib (alle imatinib resistente).
English: d Major molecular response criteria: Defined as BCR-ABL/control transcripts ≤0.1% by RQ-PCR in peripheral blood samples
Danish: d Major molekylære responskriterier: Defineret som BCR-ABL/kontroltranskriptioner ≤0,1% ved RQ-PCR i perifere blodprøver.
English: Prior imatinib (N = 46)b a Patients from Phase II paediatric study of newly diagnosed CML-CP receiving oral tablet formulation b Patients from Phase I and Phase II paediatric studies of imatinib-resistant or intolerant CML-CP receiving oral tablet formulation
Danish: Forudgående imatinib (N = 46)b a Patienter fra fase-II pædiatrisk studie i nydiagnosticeret CML-CP, som får oral tabletformulering b Patienter fra fase-I og fase-II pædiatriske studier i imitanib resistent eller -intolerant CML-CP, som får oral tabletformulering
English: • 40 mg daily for patients taking SPRYCEL 140 mg tablet daily.
Danish: • 40 mg dagligt for patienter, der tager SPRYCEL 140 mg dagligt.
English: Minimum of 7 years follow up
Danish: Mindst 7 års opfølgning
English: Holding the syringe tip firmly in the bottle, turn the bottle with the syringe upright again.
Danish: Mens sprøjtespidsen holdes godt på plads i flasken, vend flasken med sprøjten om, så den holdes lodret igen.
English: The concomitant use of dasatinib and a histamine-2 (H2) antagonist (e.g. famotidine), proton pump inhibitor (e.g. omeprazole), or aluminium hydroxide/magnesium hydroxide may reduce the exposure to dasatinib.
Danish: Samtidig brug af dasatinib og en histamin-2 (H2)-antagonist (fx famotidin), protonpumpe-hæmmer (fx omeprazol) eller aluminiumhydroxid/magnesiumhydroxid kan reducere eksponeringen af dasatinib.
English: If cytopaenia is unrelated to leukaemia, stop treatment until ANC ≥1.0 × 109/L and platelets ≥75 × 109/L and resume at the original starting dose or at a reduced dose.
Danish: Hvis cytopeni ikke er relateret til leukæmi stoppes behandlingen indtil ANC ≥ 1,0 × 109/l og trombocytter ≥ 75 × 109/l og genoptages derefter med den oprindelige startdosis eller ved en nedsat dosis.
English: Table 1: Dosage of SPRYCEL powder for oral suspension for patients with Ph+ CML-CP and paediatric patients with Ph+ ALL (10 mg/mL suspension upon constitution) Body weight (kg)
Danish: Tabel 1: Dosering af SPRYCEL pulver til oral suspension for patienter med Ph+ CML-CP og pædiatriske patienter med Ph+ ALL (10 mg/ml suspension efter rekonstitution) Legemsvægt (kg)
English: One bottle of powder for oral suspension contains 990 mg of dasatinib (as monohydrate).
Danish: Én flaske med pulver til oral suspension indeholder 990 mg dasatinib (som monohydrat).
English: PAH (pre-capillary pulmonary arterial hypertension confirmed by right heart catheterization) has been reported in association with dasatinib treatment (see section 4.8).
Danish: PAH (præ-kapillær pulmonal arteriel hypertension diagnosticeret med højresidig hjertekateterisation) er blevet rapporteret i forbindelse med dasatinib behandling (se pkt.
English: Imatinib-resistant patients
Danish: Imatinib resistente patienter
English: Outer Carton: sprycel 10 mg/mL
Danish: Ydre karton: sprycel 10 mg/ml
English: • 20 mg daily for patients taking SPRYCEL 70 mg tablet daily.
Danish: • 20 mg dagligt for patienter, der tager SPRYCEL 70 mg dagligt.
English: SPRYCEL powder for oral suspension is also available for paediatric Ph+ CML-CP and Ph+ ALL patients, and adult CML-CP patients, who cannot swallow tablets.
Danish: SPRYCEL pulver til oral suspension er også tilgængeligt til pædiatriske patienter med Ph+ CML-CP og Ph+ ALL samt voksne patienter med CML-CP, der ikke kan synke tabletter.
English: In a study of 14 healthy subjects, administration of a single 100-mg dose of SPRYCEL 22 hours following a 4-day, 40-mg omeprazole dose at steady state reduced the AUC of dasatinib by 43% and the Cmax of dasatinib by 42%.
Danish: I en undersøgelse med 14 raske forsøgspersoner, resulterede administration af en enkeldosis på 100 mg SPRYCEL 22 timer efter en dosis på 40 mg omeprazol i 4 dage, ved steady state i en reduktion af AUC for dasatinib på 43% og Cmax for dasatinib på 42%.
English: The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily.
Danish: Anbefalet startdosis ved CML i kronisk fase er 100 mg dasatinib én gang dagligt.
English: The starting dose recommended for adult patients with chronic phase CML is 100 mg once a day.
Danish: Den anbefalede startdosis til voksne patienter med CML i kronisk fase er 100 mg 1 gang dagligt.
English: SPRYCEL 20 mg, 50 mg or 70 mg film-coated tablets are available in cartons containing 56 film-coated tablets in 4 calendar blisters of 14 film-coated tablets each, and in cartons containing 60 x 1 film-coated tablets in perforated unit dose blisters.
Danish: SPRYCEL 20 mg, 50 mg eller 70 mg filmovertrukne tabletter fås i æsker med 56 filmovertrukne tabletter i 4 kalender-blisterkort, der hver indeholder 14 filmovertrukne tabletter, samt i æsker med 60 × 1 filmovertrukne tabletter i perforerede engangsdosis-blisterkort.
English: One patient (< 1%) in each group experienced a QTcF > 500 msec.
Danish: En patient (< 1%) i hver gruppe havde QTcF > 500 msek.
English: Common arthralgia, myalgia, muscular weakness, musculoskeletal stiffness, muscle spasm Uncommon rhabdomyolysis, osteonecrosis, muscle inflammation, tendonitis, arthritis
Danish: Almindelig artralgi, myalgi, muskelsvaghed, muskulosketal stivhed, muskelspasmer Ikke almindelig rabdomyolyse, osteonekrose, muskelinflammation, tendonitis, artritis
English: Daily Dose, mL (mg)
Danish: Daglig dosis, ml (mg)
English: In Ph+ ALL paediatric patients with non-haematologic adverse reactions, if needed, one level of dose reduction should be followed, according to the dose reduction recommendations for haematologic adverse reactions that are described above.
Danish: Hos pædiatriske patienter med Ph+ ALL med ikke-hæmatologiske bivirkninger bør dosis reduceres ét niveau efter behov i henhold til anbefalingerne for dosisreduktion for hæmatologiske bivirkninger beskrevet ovenfor.
English: Laboratory test abnormalities Haematology
Danish: Afvigelser i laboratorieundersøgelser Hæmatologi
English: Effects on growth and development in paediatric patients In paediatric trials of SPRYCEL in imatinib-resistant/intolerant Ph+ CML-CP paediatric patients and treatment-naive Ph+ CML-CP paediatric patients after at least 2 years of treatment, treatment-related adverse events associated with bone growth and development were reported in 6 (4.6%) patients, one of which was severe in intensity (Growth Retardation Grade 3).
Danish: Effekter på vækst og udvikling hos pædiatriske patienter I pædiatriske studier med SPRYCEL hos imatinib resistente/intolerante pædiatriske patienter med Ph+ CML-CP og behandlingsnaive pædiatriske patienter med Ph+ CML-CP efter mindst 2 års behandling blev behandlingsrelaterede bivirkninger associeret med knoglevækst og -udvikling rapporteret hos 6 (4,6%) patienter, hvoraf én var svær i intensitet (grad 3 væksthæmning).
English: DO NOT USE A DISHWASHER
Danish: MÅ IKKE VASKES I OPVASKEMASKINE
English: Data from healthy subjects administered a single 100 mg dose of dasatinib 30 minutes following a high-fat meal indicated a 14% increase in the mean AUC of dasatinib.
Danish: Data fra raske frivillige, der fik enkeltdosis dasatinib 100 mg 30 minutter efter et fedtrigt måltid, viste en 14% stigning i gennemsnitligt AUC for dasatinib.
English: A different spectrum of mutation was detected in the imatinib treatment arm. Dasatinib does not appear to be active against the T315I mutation, based on in vitro data.
Danish: Baseret på in vitro-data synes dasatinib ikke at være aktiv over for T315I-mutationen.
English: Chronic phase CML - Resistance or intolerance to prior imatinib therapy
Danish: CML i kronisk fase - resistens eller intolerans over for tidligere imatinib behandling
English: Other medicinal products that induce CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, phenobarbital or herbal preparations containing Hypericum perforatum, also known as St. John´s Wort) may also increase metabolism and decrease dasatinib plasma concentrations.
Danish: Andre lægemidler, der inducerer CYP3A4-aktivitet (fx dexamethason, phenytoin, carbamazepin, phenobarbital eller naturlægemidler, der indeholder Hypericum perforatum, også kendt som perikon), kan øge metabolismen og reducere plasmakoncentrationer af dasatinib.
English: Unopened bottle 2 years.
Danish: Uåbnet flaske
English: Brain: stroke, temporary episode of neurologic dysfunction caused by loss of blood flow, facial nerve paralysis, dementia
Danish: Hjerne: slagtilfælde, midlertidig episode med neurologiske forstyrrelser på grund af nedsat blodtilførsel, lammelse af ansigtsnerverne, demens Immunsystemet: alvorlig allergisk reaktion
English: SPRYCEL contains lactose
Danish: SPRYCEL indeholder lactose
English: Remove the syringe from the bottle being careful not to depress the plunger.
Danish: Fjern sprøjten fra flasken uden at trykke stemplet ned.
English: A statistically significant increase in the combined incidence of squamous cell carcinomas and papillomas in the uterus and cervix of high-dose females and of prostate adenoma in low-dose males was noted.
Danish: Der blev observeret en klinisk signifikant stigning i den samlede hyppighed af planocellulært karcinom og papillomer i uterus og cervix i høj-dosis hunrotter og prostataadenom i lav-dosis hanrotter.
English: Common febrile neutropaenia Uncommon lymphadenopathy, lymphopaenia
Danish: Almindelig febril neutropeni Ikke almindelig lymfadenopati, lymfopeni
English: In paediatric trials of SPRYCEL in combination with chemotherapy in newly diagnosed Ph+ ALL paediatric patients after a maximum of 2 years of treatment, treatment-related adverse events associated with bone growth and development were reported in 1 (0.6%) patient.
Danish: I pædiatriske studier med SPRYCEL i kombination med kemoterapi hos nydiagnosticerede pædiatriske patienter med Ph+ ALL blev der, efter maksimalt 2 års behandling, rapporteret behandlingsrelaterede bivirkninger associeret med knoglevækst og udvikling hos 1 (0,6%) patient.
English: SPRYCEL 80 mg, 100 mg or 140 mg film-coated tablets are available in cartons containing 30 x 1 film-coated tablets in perforated unit dose blisters.
Danish: SPRYCEL 80 mg, 100 mg eller 140 mg filmovertrukne tabletter fås i æsker med 30 × 1 filmovertrukne tabletter i perforerede engangsdosis-blisterkort.
English: Based on the Kaplan-Meier estimates, 95% (95% CI: [92%-98%]) of the patients maintained MCyR for 1 year and 88% (95% CI: [83%-93%]) maintained MCyR for 2 years.
Danish: Baseret på Kaplan-Meier-estimaterne opretholdt 95% (95% CI: [92%-98%]) af patienterne MCyR i et år og 88% (95% CI: [83%-93%]) opretholdt MCyR i to år.
English: The proportion of patients who maintained CCyR for 1 year was 97% (95% CI: [94%-99%]) and for 2 years was 90% (95% CI: [86%-95%]).
Danish: Andelen af patienter som opretholdt CCyR i et år var 97% (95% CI: [94%-99%]) og 90% (95% CI: [86%-95%]) i to år.
English: Bleeding drug-related adverse reactions, ranging from petechiae and epistaxis to grade 3 or 4 gastrointestinal haemorrhage and CNS bleeding, were reported in patients taking SPRYCEL (see section 4.4).
Danish: Lægemiddelrelaterede blødningsbivirkninger spændende fra petekkier og epistaxis til grad 3 eller 4 gastrointestinal blødning og blødning i centralnervesystemet (CNS) er rapporteret hos patienter, der tager SPRYCEL (se pkt.
English: Two randomised, open-label studies were conducted to evaluate the efficacy of dasatinib administered once daily compared with dasatinib administered twice daily.
Danish: Der er gennemført 2 randomiserede, åbne studier for at evaluere effekten af dasatinib administreret én gang dagligt, sammenlignet med dasatinib administreret 2 gange dagligt.
English: Digestive problems: diarrhoea, feeling or being sick (nausea, vomiting) Skin, hair, eye, general: skin rash, fever, swelling around the face, hands and feet, headache, feeling tired or weak, bleeding
Danish: Fordøjelsesproblemer: diarré, kvalme eller opkastning Hud, hår, øjne, generelt: udslæt, feber, hævelse af ansigt, hænder og fødder, hovedpine, følelse af træthed eller svaghed, blødning
English: Common appetite disturbancesa, hyperuricaemia Uncommon tumour lysis syndrome, dehydration, hypoalbuminemia, hypercholesterolemia
Danish: Almindelig appetitforstyrrelsera, hyperurikæmi Ikke almindelig tumorlysesyndrom, dehydrering, hypoalbuminæmi, hyperkolesterolæmi
English: Table 9: Efficacy results from a phase 3 study of newly diagnosed patients with chronic phase CML
Danish: Tabel 9: Effektresultater fra et fase 3-studie hos patienter med nyligt diagnosticeret CML i kronisk fase
English: b Haematologic response criteria (all responses confirmed after 4 weeks): Major haematologic response (MaHR) = complete haematologic response (CHR) + no evidence of leukaemia (NEL).
Danish: b Hæmatologiske responskriterier (alle responser blev bekræftet efter 4 uger): Større hæmatologisk respons: (MaHR)
English: 20 to less than 30
Danish: 20 til under 30
English: 2 If cytopaenia is unrelated to leukaemia, stop treatment until ANC ≥ 1.0 x 109/L and platelets ≥ 20 x 109/L and resume at the original starting dose.
Danish: 2 Hvis cytopeni ikke er relateret til leukæmi stoppes behandlingen, indtil ANC ≥ 1,0 × 109/l og trombocytter ≥ 20 × 109/l og genoptages med den oprindelige startdosis.
English: The time to MMR was consistently shorter in dasatinib-treated patients compared with imatinib-treated patients.
Danish: Tid til MMR var konsekvent kortere hos dasatinib behandlede patienter sammenlignet med imatinib behandlede patienter.
English: The following can all be signs of serious side effects: if you have chest pain, difficulty breathing, coughing and fainting if you experience unexpected bleeding or bruising without having an injury if you find blood in your vomit, stools or urine, or have black stools if you get signs of infections such as fever, severe chills if you get fever, sore mouth or throat, blistering or peeling of your skin and/or mucous membranes Contact your doctor immediately if you notice any of the above.
Danish: Følgende kan alle være tegn på alvorlige bivirkninger: hvis du har brystsmerter, vejrtrækningsbesvær, hoste, eller hvis du besvimer hvis du får uventet blødning eller blå mærker uden at du har slået dig hvis du har blod i opkast, afføring eller urin, eller sortfarvet afføring hvis du får tegn på infektion, som for eksempel feber eller voldsomme kulderystelser hvis du får feber, ømhed i munden eller halsen, blæredannelse eller afskalning af huden og/eller slimhinderne Kontakt straks lægen, hvis du får en eller flere af ovenstående bivirkninger.
English: The once daily schedule demonstrated comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint (difference in MaHR 0.8%; 95% confidence interval [-7.1% - 8.7%]); however, the 140 mg once daily regimen demonstrated improved safety and tolerability.
Danish: Dosering én gang dagligt viste sammenlignelig effekt (non-inferioritet) med dosering 2 gange dagligt med hensyn til det primære effektendepunkt (forskel i MaHR 0,8%; 95% konfidensinterval [-7,1% - 8,7%]); behandling med 140 mg én gang dagligt viste imidlertid forbedret sikkerhed og tolerabilitet.
English: The following can all be signs of serious side effects: if you have chest pain, difficulty breathing, coughing and fainting if you experience unexpected bleeding or bruising without having an injury if you find blood in your vomit, stools or urine, or have black stools if you get signs of infections such as fever, severe chills if you get fever, sore mouth or throat, blistering or peeling of your skin and/or mucous membranes
Danish: Følgende kan alle være tegn på alvorlige bivirkninger: hvis du har brystsmerter, vejrtrækningsbesvær, hoste, eller hvis du besvimer hvis du får uventet blødning eller blå mærker uden at du har slået dig hvis du har blod i opkast, afføring eller urin, eller sortfarvet afføring hvis du får tegn på infektion, som for eksempel feber eller voldsomme kulderystelser hvis du får feber, ømhed i munden eller halsen, blæredannelse eller afskalning af huden og/eller slimhinderne
English: • 20 mg daily for patients taking SPRYCEL 100 mg tablet daily.
Danish: • 20 mg dagligt for patienter, der tager SPRYCEL 100 mg dagligt.
English: Their occurrence is earlier and more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML.
Danish: Forekomsten er tidligere og hyppigere hos patienter med CML eller Ph+ ALL i fremskreden fase end med CML i kronisk fase.
English: c Major molecular response (at any time) was defined as BCR ABL ratios ≤ 0.1% by RQ PCR in peripheral blood samples standardised on the International scale.
Danish: c Betydeligt molekylært respons (til enhver tid) er defineret som BCR-ABL forhold ≤ 0,1% ved RQ-PCR i perifere blodprøver, som er standardiseret efter den internationale skala.
English: In CML-CP paediatric patients with non-haematologic adverse reactions, the dose reduction recommendations for haematologic adverse reactions that are described above should be followed.
Danish: Hos pædiatriske patienter med CML-CP med ikke-hæmatologiske bivirkninger bør anbefalingerne for dosisreduktion for hæmatologiske bivirkninger beskrevet ovenfor følges.
English: In all SPRYCEL treated patients with chronic phase CML, severe fluid retention occurred in 32 patients (6%) receiving SPRYCEL at the recommended dose (n=548).
Danish: Der forekom svær væskeretention hos 32 patienter (6%) ud af alle patienter med CML i kronisk fase, der fik SPRYCEL ved den anbefalede dosis (n=548).
English: Two randomised, open-label Phase III studies were conducted to evaluate the efficacy of dasatinib administered once daily compared with dasatinib administered twice daily.
Danish: Der er gennemført 2 randomiserede, åbne fase III-studier for at evaluere effekten af dasatinib, administreret én gang dagligt sammenlignet med dasatinib, administreret 2 gange dagligt.
English: In the Phase II paediatric study, in patients receiving the tablet formulation, estimated 24-month PFS rate among the 51 patients with newly diagnosed CML-CP was 94.0% (82.6, 98.0), and 81.7% (61.4, 92.0) among the 29 patients with imatinib-resistant/intolerant CML-CP. After 24 months of follow-up, OS in newly diagnosed patients was 100%, and 96.6% in imatinib-resistant or intolerant patients.
Danish: I det pædiatriske fase-II-studie med patienter, der fik tabletformuleringen, var den estimerede 24måneders PFS blandt de 51 patienter med nydiagnosticeret CML-CP 94,0% (82,6; 98,0) og 81,7% (61,4; 92,0) blandt de 29 patienter med imatinib resistent/intolerant CML-CP.
English: Uncommon renal impairment (including renal failure), urinary frequency, proteinuria
Danish: Ikke almindelig nyreinsufficiens (inklusive nyresvigt), hyppig vandladning, proteinuri
English: By 5 years 42%, p<.0251
Danish: Ved år 5 p<0,0251
English: An open-label, single-arm, multicentre study was conducted in patients intolerant or resistant to imatinib.
Danish: Der er gennemført et åbent, enkeltarms-, multicenter-studie med patienter med intolerans eller resistens over for imatinib.
English: Long-term suppression of gastric acid secretion by H2 antagonists or proton pump inhibitors (e.g. famotidine and omeprazole) is likely to reduce dasatinib exposure.
Danish: Langvarig suppression af mavesyresekretion ved H2-antagonister eller protonpumpe-hæmmere (fx famotidin og omeprazol) vil sandsynligvis reducere eksponeringen af dasatinib.
English: MMR (95% CI) Newly diagnosed (N = 51)a
Danish: MMR (95% CI) Nydiagnosticeret (N = 51)a